Type 2 diabetes is a chronic and progressive disease associated with a series of complications, including major
adverse cardiovascular events. As adequate glycemic control has been proven to reduce this risk, sodium-glucose
cotransporter 2 (SGLT2) inhibitors are among the promising medications in managing patients with type
2 diabetes. The current systematic review aimed to explore the SGLT2 inhibitor effects on cardiovascular outcomes.
A filtration procedure was used to remove duplicates and irrelevant publications. The online databases such as PubMed, Google Scholar, and EBSCO were used to perform a literature search, without any date or language restrictions. We used a combination of relevant search terms “diabetes, sodium-glucose cotransporter 2 inhibitors, and cardiovascular." We independently identified publications and systematically screened titles, abstracts, and full texts of the collected publications. Among 200 articles initially selected based on the title and abstract, 197 articles were excluded. Finally, three articles were selected and included in the review. All three studies concerned about the cardiovascular safety of SGLT2 inhibitors and showed that, compared with placebo, empagliflozin, canagliflozin, and dapagliflozin safely lower blood glucose with a reduction in the major adverse cardiovascular events. Across the three trials, empagliflozin, canagliflozin, and dapagliflozin resulted in a consistent class effect on cardiovascular outcomes.
Cardiovascular events, SGLT2 inhibitor, diabetes.â€Ž
Hyperglycemia in acute ischemic stroke: physiopathological and therapeutic complexity.
Ferrari F, Moretti A, Villa RF
Neural regeneration research. 2022; 17(2): 292-299
A not so perfect plan: An examination of the differential influence of multidimensional perfectionism on missed and gained events during the COVID-19 pandemic.
Levine SL, Andrade G, Koestner R
Personality and individual differences. 2022; 184(): 111214
Baculoviral inhibitor of apoptosis protein repeat-containing protein 3 delays early Wallerian degeneration after sciatic nerve injury.
Cai M, Shao J, Yung B, Wang Y, Gao NN, Xu X, Zhang HH, Feng YM, Yao DB
Neural regeneration research. 2022; 17(4): 845-853
Stroke recovery enhancing therapies: lessons from recent clinical trials.
Rogalewski A, SchĂ¤bitz WR
Neural regeneration research. 2022; 17(4): 717-720
Assessment of structural brain changes in patients with type 2 diabetes mellitus using the MRI-based brain atrophy and lesion index.
Zhao H, Wang F, Luo GH, Lei H, Peng F, Ren QP, Chen W, Wu YF, Yin LC, Liu JC, Pan SN
Neural regeneration research. 2022; 17(3): 618-624